Satellos Bioscience

Satellos Bioscience Inc. is a regenerative medicine company with the slogan "Rebuilding muscle from within." The company was founded in 2018 in Canada and is focused on developing novel therapeutics to stimulate or restore muscle regeneration in severe disorders. Their lead program targets Duchenne muscular dystrophy, aiming to correct dysregulated muscle stem-cell polarity, which is believed to be a root cause of the disease's progressive nature. Satellos applies its proprietary discovery platform, MyoReGenX, to identify regulatory pathways and drug candidates for muscle disorders where stem cell polarity is dysregulated. In their latest funding round on 17 May 2023, Satellos Bioscience Inc. secured a $55.00M Post-IPO Equity investment from a consortium of investors including Qiming Venture Partners USA, Perceptive Advisors, Soleus Capital, Avidity Partners, FMB Research, and Allostery Investments. Satellos' approach addresses the critical underlying role of defects in muscle regeneration in numerous disorders, spanning rare diseases to mass market indications. Their focus on regenerative medicine and the promising potential of their lead program for Duchenne muscular dystrophy makes the company an attractive prospect for investors in the Health Care and Pharmaceutical industries.